ISSN: 0034-8376
eISSN: 2564-8896






Type 1 Diabetes Care in Mexico: An Analysis of the RENACED-DT1 National Registry



Raquel N. Faradji-Hazán, Clínica EnDi, Mexico City; School of Medicine, Instituto Tecnológico de Monterrey, Mexico City; Mexico
Marisol Valenzuela-Lara, Centro Nacional para la Prevención y el Control del VIH y el Sida, Mexico City, Mexico
Ana P. Díaz-Barriga Menchaca, School of Medicine, Instituto Tecnológico de Monterrey, Mexico City, Mexico
Paloma Almeda-Valdés, Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, D.F., Mexico
Neftali E. Antonio-Villa, Department of Endocrinology and Metabolism, Metabolic Diseases Research Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMyNSZ), Mexico City; MD/PhD Programa de Estudios Combinados en Medicina (PECEM) Program, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Mexico City; Mexico
Maricela Vidrio-Velázquez, Department of Endocrinology, Hospital General Regional # 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jal., Mexico
Laura Islas-Ortega, Pediatric Endocrinology Service, Hospital del Niño DIF Hidalgo, Pachuca, Hgo., Mexico
Angélica Martínez-Ramos-Méndez, Pediatric Endocrinology Service, Hospital Español, Mexico City, Mexico
Karla L. Sánchez-Ruiz, Clínica de Diabetes, Secretaría de Salud del Estado de Durango, Dgo., Mexico
Alicia E. Yepez-Rodríguez, Internal Medicine and Endocrinology Service, Corporativo Hospital Satélite, Mex., Mexico
Guillermo González-Gálvez, Instituto Jalisciense de Investigación en Diabetes y Obesidad, Guadalajara, Jal., Mexico
Ricardo S. Niño-Vargas, Centro para la Prevención y Atención Integral del VIH/SIDA de la Ciudad de México, Mexico City, Mexico
María E. Sainz de la Maza-Viadero, Clínica EnDi, Mexico City, Mexico
Carlos Magis-Rodríguez, Faculty of Medicine, UNAM, Mexico City, Mexico
on behalf of RENACED Diabetes Tipo 1 Research Group,


Background: Information regarding diagnosis, treatment, and follow-up of patients with type 1 diabetes (PWT1D) in Mexico is limited. We developed an on-line platform Registro Nacional de Pacientes con Diabetes Tipo 1 (RENACED-DT1). Objective: The objective of the study was to describe the characteristics and healthcare of PWT1D registered in RENACED-DT1. Methods: Analyses of 965 PWT1D from July 2014 to January 2018 in different endocrinology clinics around Mexico. Results: Sixty-one percent were female with median age of 21 years, age at diagnosis 11 years, and disease duration at inclusion 8.2 years. Treatment regimen was basal-bolus in 61% and insulin-pumps in 21% (mainly in the private sector); 33.3% with self-monitoring of blood-glucose (SMBG) >- 4 times/day. Mean HbA1c at last follow-up was 8.7 +- 2.1% (72+-23 mmol/mol), 18% had HbA1c < 7% (53 mmol/mol), and 35% > 9% (75 mmol/mol). SMBG >- 4 times/day was associated with HbA1c < 7%. Time since diagnosis > 10 years, female sex, BMI >- 30 kg/m2, SMBG < 4 times/day, and any hypoglycemia were associated with microvascular complications (p < 0.05). Conclusions: Percentage of patients achieving HbA1c < 7% is low; increased blood glucose monitoring is associated with better glycemic control. The achievement of optimal glycemic control must be increased to reduce the incidence of chronic complications and improve quality of life in PWT1D.



Keywords: Diabetes mellitus type 1. Registries. Mexico. Glycated hemoglobin A1c.